kabutan

FunPep Company Limited(4881) Summary

4881
TSE Growth
FunPep Company Limited
102
JPY
+2
(+2.00%)
Mar 13, 3:30 pm JST
0.63
USD
Mar 13, 2:30 am EDT
Result
PTS
outside of trading hours
100.5
Mar 13, 11:57 pm JST
Summary Chart Historical News Financial Result
PER
PBR
2.90
Yield
ー%
Margin Trading Ratio
Stock Price
Mar 13, 2026
Opening Mar 13, 9:00 am
98 JPY 0.61 USD
Previous Close Mar 12
100 JPY 0.62 USD
High Mar 13, 11:11 am
104 JPY 0.65 USD
Low Mar 13, 9:08 am
96 JPY 0.60 USD
Volume
1,532,600
Trading Value
0.15B JPY 0.96M USD
VWAP
100.32 JPY 0.63 USD
Minimum Trading Value
10,200 JPY 63 USD
Market Cap
4.17B JPY 0.03B USD
Number of Trades
466
Liquidity & Number of Trades
As of Mar 13, 2026
Liquidity
Mid
1-Year Average
271
1-Year High Mar 6, 2026
5,097
Margin Trading
Date Short Interest Long Margin Positions Ratio
Mar 6, 2026 27,000 4,386,500 162.46
Feb 27, 2026 2,000 3,521,000 1760.50
Feb 20, 2026 0 3,354,500
Feb 13, 2026 0 3,471,300
Feb 6, 2026 800 3,674,700 4593.38
Company Profile
FunPep Company Limited is a spin-off from Osaka University's Institute for Protein Research, focusing on research and development of pharmaceuticals using functional peptides.
Sector
Pharmaceuticals
FunPep Company Limited engages in the research and development of pharmaceuticals and other products using functional peptides. The company's strength lies in its proprietary drug discovery platform technology "STEP UP" for antibody-inducing peptides, enabling the creation of development candidates for various target proteins as alternatives to antibody drugs. Additionally, FunPep is advancing the development of SR-0379, a treatment for skin ulcers. The company aims to generate new development candidates through collaborative research with universities and promotes development through partnerships with pharmaceutical companies. In the future, FunPep aspires to achieve significant profit growth through royalty income from the commercialization of its development products. The company's mission is to contribute to society by developing new pharmaceuticals that help reduce medical costs and patient burden.